(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine
Glioma, Malignant
Nuvation Bio Inc.Small moleculePhase 1Dormant
D
25/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 10/ 100
- Competitive Position
- 81/ 100
Competitive context
109 Active assets in the Glioma, Malignant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Kailin Yang, MD, PhD | Phase 2 | BB |
Marizomib Aadi Bioscience, Inc. | Phase 2 | BB |
Valaciclovir Trogenix ltd | Phase 2 | BB |
Valproic Acid Virginia Commonwealth University | Phase 2 | BB |
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE Oblato, Inc. | Phase 2 | BB |
View all 50 →
Same molecule, other indications
(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →